logo
ResearchBunny Logo
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19

Medicine and Health

Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19

T. O. Jensen, G. A. Grandits, et al.

Experience groundbreaking insights into the effectiveness of neutralizing monoclonal antibodies (nmAbs) for hospitalized COVID-19 patients. This research, conducted by renowned experts including Tomas O Jensen and Greg A Grandits, reveals the complex interactions of virologic and immunologic markers, highlighting a notable antiviral effect of nmAbs on plasma N-Ag levels, despite no significant differences in inflammation or clinical outcomes.

00:00
00:00
~3 min • Beginner • English
Abstract
Background. Neutralizing monoclonal antibodies (nmAbs) failed to show clear benefit for hospitalized patients with coronavirus disease 2019 (COVID-19). Dynamics of virologic and immunologic biomarkers remain poorly understood. Methods. Participants enrolled in the Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) trials were randomized to nmAb versus placebo. Longitudinal differences between treatment and placebo groups in levels of plasma nucleocapsid antigen (N-Ag), anti-nucleocapsid antibody, C-reactive protein (CRP), interleukin-6 (IL-6), and D-dimer at enrollment, day 1, 3, and 5 were estimated using linear mixed models. A 7-point pulmonary ordinal scale assessed at day 5 was compared using proportional odds models. Results. Analysis included 2149 participants enrolled between August 2020 and September 2021. Treatment resulted in 20% lower levels of plasma N-Ag compared with placebo (95% confidence interval [CI], 12%–27%; P < .001), and a steeper rate of decline through the first 5 days (P < .001). The treatment difference did not vary between subgroups, and no difference was observed in trajectories of other biomarkers or the day 5 pulmonary ordinal scale. Conclusions. nmAb treatment showed an antiviral effect assessed by plasma N-Ag among hospitalized patients with COVID-19 without blunting the endogenous anti-nucleocapsid antibody response, and no effect on systemic inflammation or day 5 clinical status. Clinical Trials Registration. NCT04501978.
Publisher
The Journal of Infectious Diseases
Published On
Nov 09, 2023
Authors
Tomas O Jensen, Greg A Grandits, Mamta K Jain, Thomas A Murray, Birgit Grund, Kathryn Shaw-Saliba, Michael A Matthay, Mahsa Abassi, Magdalena Ardelt, Jason V Baker, Peter Chen, Robin L Dewar, Anna L Goodman, Timothy J Hatlen, Helene C Highbarger, Mark Holodniy, Perrine Lallemand, Sylvain Laverdure, Bradley G Leshnower, David Looney, Charalampos D Moschopoulos, Henry Mugerwa, Daniel D Murray, Eleftherios Mylonakis, Stephanie Nagy-Agren, M Tauseef Rehman, Adam Rupert, Randy A Stevens, Stuart Turville, Amy Weintrob, Katherine Wick, Jens Lundgren, Emily Ray Ko
Tags
COVID-19
neutralizing monoclonal antibodies
plasma nucleocapsid antigen
biomarkers
systemic inflammation
clinical outcomes
virologic dynamics
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny